摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[3-(4-penylpiperazin-1-yl)propyl]-1H-isoindole-1,3(2H)-dione | 25557-30-6

中文名称
——
中文别名
——
英文名称
2-[3-(4-penylpiperazin-1-yl)propyl]-1H-isoindole-1,3(2H)-dione
英文别名
2-(3-(4-phenylpiperazin-1-yl)propyl)isoindoline-1,3-dione;2-[3-(4-phenylpiperazin-1-yl)propyl]isoindoline-1,3-dione;N-(3-(4-phenylpiperazin-1-yl)propyl)phthalimide;N-[3-(4-phenyl-piperazin-1-yl)-propyl]-phthalimide;3-(4-phenylpiperazin-1-yl)-propan-1-ylphthalimide;N-[3-(4-phenyl-1-piperazinyl)propyl]phthalimide;2-[3-(4-Phenyl-piperazin-1-yl)-propyl]-isoindole-1,3-dione;2-[3-(4-phenylpiperazin-1-yl)propyl]isoindole-1,3-dione
2-[3-(4-penylpiperazin-1-yl)propyl]-1H-isoindole-1,3(2H)-dione化学式
CAS
25557-30-6
化学式
C21H23N3O2
mdl
——
分子量
349.433
InChiKey
IXYMLHRXRRYXSJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    135-137 °C
  • 沸点:
    521.9±45.0 °C(Predicted)
  • 密度:
    1.224±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    43.9
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:d1ae075d75f6da4174f334d815f4e4d8
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-[3-(4-penylpiperazin-1-yl)propyl]-1H-isoindole-1,3(2H)-dione三乙胺甲胺 作用下, 以 四氢呋喃甲醇乙腈 为溶剂, 反应 4.0h, 生成 N-benzyl-N-((3-(4-phenylpiperazin-1-yl)propylcarbamoyl)methyl)aminoacetic acid
    参考文献:
    名称:
    Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors
    摘要:
    As the matrix metalloproteinases (MMPs) can be massively up-regulated in degenerative tissues and degrade the extracellular matrix, these key enzymes are promising targets for the therapy of cancer and other degenerative diseases. Here, we are presenting a series of new non-peptidic hydroxamate-based matrix metalloproteinase inhibitors, MMPIs, incorporating the iminodiacetic (IDA) hydroxamic acid scaffold, as mimics of truncated peptidic MMPIs. A series of alkylaryl and sulfonylaryl groups, on the IDA basic scaffold, was investigated with the aim of improving potency and selectivity against MMPs involved in degenerative diseases. The sulfonamide based IDA derivatives studied (compounds B1-B3) showed to be potent (nM range) against deep S1' pocket MMPs enzymes (i.e., MMP-2). (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2006.07.011
  • 作为产物:
    描述:
    N-苯基哌嗪 以42%的产率得到
    参考文献:
    名称:
    GLENNON, RICHARD A.;NAIMAN, NOREEN A.;LYON, ROBERT A.;TITELER, MILT, J. MED. CHEM., 31,(1988) N 10, C. 1968-1971
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Binding Kinetics of ZM241385 Derivatives at the Human Adenosine A<sub>2A</sub>Receptor
    作者:Dong Guo、Lizi Xia、Jacobus P. D. van Veldhoven、Marc Hazeu、Tamara Mocking、Johannes Brussee、Adriaan P. IJzerman、Laura H. Heitman
    DOI:10.1002/cmdc.201300474
    日期:2014.4
    compound’s binding kinetics have been largely ignored, the importance of which is now being increasingly recognized. In the present study, we performed an extensive structure–kinetics relationship (SKR) study in addition to a traditional SAR analysis at the adenosine A2A receptor (A2AR). The ensemble of 24 A2AR compounds, all triazolotriazine derivatives resembling the prototypic antagonist ZM241385 (4‐(
    经典药物的设计和开发主要依赖于亲和力或效价驱动的结构-活性关系(SAR)。迄今为止,给定化合物的结合动力学已被很大程度上忽略,其重要性现在越来越被人们所认识。在本研究中,除了对腺苷A 2A受体(A 2A R)进行传统的SAR分析外,我们还进行了广泛的结构动力学关系(SKR)研究。由24 A 2A R化合物组成的化合物,所有三唑三嗪衍生物均类似于原型拮抗剂ZM241385(4-(2-((7-氨基-2-(呋喃-2-基)-[1,2,4]三唑[1, 5一] [1,3,5] triazin-5-基)氨基)乙基)苯酚)在亲和力上仅显示微小差异,尽管它们与受体的解离速率差异很大。我们相信,像我们对A 2A R所做的那样,SKR和SAR分析的这种结合对于G蛋白偶联受体的超家族将具有普遍的重要性,因为它可以作为调整配体之间相互作用的新策略和受体。
  • [EN] PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR)<br/>[FR] PHENYL CARBAMATES ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME HYDROLASE D'AMIDES D'ACIDES GRAS (FAAH) ET MODULATEURS DU RÉCEPTEUR D3 DE LA DOPAMINE (D3DR)
    申请人:FOND ISTITUTO ITALIANO DI TECNOLOGIA
    公开号:WO2015007615A1
    公开(公告)日:2015-01-22
    The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar', R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same time inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR), their methods of preparation, formulations and therapeutic applications thereof.
    该发明提供了式(I)的化合物或其药用可接受的盐,其中Ar',R1,R2,R3,R4,X,Y如发明描述中所定义,作为多靶点定向配体(MTDLs),同时是脂肪酸酰胺水解酶(FAAH)酶的抑制剂和D3多巴胺受体(D3DR)的调节剂,以及它们的制备方法、配方和治疗应用。
  • Computer‐Aided Search for 5‐Arylideneimidazolone Anticancer Agents Able To Overcome ABCB1‐Based Multidrug Resistance
    作者:Aneta Kaczor、Nikoletta Szemerédi、Katarzyna Kucwaj‐Brysz、Monika Dąbrowska、Małgorzata Starek、Gniewomir Latacz、Gabriella Spengler、Jadwiga Handzlik
    DOI:10.1002/cmdc.202100252
    日期:2021.8.5
    ABCB1 modulation is an interesting strategy in the search for new anticancer agents that can overcome multidrug resistance (MDR). Hence, 17 new 5-arylideneimidazolones containing an amine moiety, as potential ABCB1 inhibitors, were designed, synthesized, and investigated. The series was tested in both parental (PAR) and multidrug-resistant (MDR) ABCB1-overexpressing T-lymphoma cancer cells using cytotoxicity
    ABCB1 调节是寻找可以克服多药耐药性 (MDR) 的新抗癌药物的有趣策略。因此,设计、合成和研究了 17 种新的含有胺部分的 5-亚芳基咪唑酮,作为潜在的 ABCB1 抑制剂。使用细胞毒性测定法在亲本 (PAR) 和多药耐药 (MDR) ABCB1 过度表达的 T 淋巴瘤癌细胞中测试了该系列。ABCB1 调节活性在罗丹明 123 积累测试中进行了检查,然后通过 Pgp-Glo™ 测定来确定最活跃的化合物对 ATP 酶活性的影响。在计算机中评估了两者的亲脂性和实验(RP-TLC)。进行了针对 ABCB1 调制的基于药效团的分子建模。这些研究允许鉴定比多柔比星更有效的抗癌剂(对氟亚苄基衍生物),对 MDR T 淋巴瘤细胞具有高度选择性作用(选择性指数 >40)。大多数研究的化合物显示出 ABCB1 调节作用。特别是,两种 5-苄氧基亚苄基衍生物显示出几乎与 tariquidar 一样强的活性。
  • Synthesis and anti-inflammatory activity of some novel 3-phenyl-N-[3-(4-phenylpiperazin-1yl)propyl]-1H-pyrazole-5-carboxamide derivatives
    作者:Lingaiah Nagarapu、Jhansi Mateti、Hanmant K. Gaikwad、Rajashaker Bantu、M. Sheeba Rani、N.J. Prameela Subhashini
    DOI:10.1016/j.bmcl.2011.05.105
    日期:2011.7
    A new series of 3-phenyl-N-[3-(4-phenylpiperazin-1yl)propyl]-1H-pyrazole-5-carboxamide derivatives were synthesized and investigated their anti-inflammatory activities using carrageenan-induced rat paw edema model in vivo. All the synthesized compounds were found to be potent anti-inflammatory agents.
    合成了一系列新的3-苯基-N- [3-(4-苯基哌嗪-1基)丙基] -1H-吡唑-5-羧酰胺衍生物,并用角叉菜胶诱导的大鼠爪水肿模型研究了它们的抗炎活性。体内。发现所有合成的化合物都是有效的抗炎药。
  • Synthesis and evaluation of antiproliferative activity of novel quinazolin-4(3H)-one derivatives
    作者:Ramineni Venkatesh、Suresh Kasaboina、Sridhara Janardhan、Nishant Jain、Rajashaker Bantu、Lingaiah Nagarapu
    DOI:10.1007/s00044-016-1632-9
    日期:2016.9
    Two series of novel quinazolin-4(3H)-one derivatives (10a–g and 11a–g) have been synthesized and evaluated for their in vitro antiproliferative activity against human HeLa, MIAPACA, MDA-MB-231, and IMR-31 cancer cell lines. The synthesized compounds were characterized by spectral (Fourier transform infrared, 1H nuclear magnetic resonance, 13C nuclear magnetic resonance, high-resolution mass spectra)
    合成了两个系列的新型喹唑啉-4(3 H)-一衍生物(10a–g和11a–g),并评估了它们对人HeLa,MIAAPACA,MDA-MB-231和IMR-31的体外抗增殖活性癌细胞系。合成的化合物通过光谱(傅立叶红外光谱,1 H核磁共振,13 C核磁共振,高分辨率质谱)进行表征。其中,化合物11e和11g对MIAPACA人癌细胞系显示出强大的体外抗增殖活性,GI 50值为0.02,小于0.01μM。明显地,化合物10a,10b,10c,10g,11b,11c,11d,11e,11f显示了针对人癌细胞系MIAPACA,MDA-MB-231和IMR-31的GI 50值为0.1至0.87μM的活性。我们已经探索了HDAC8和EHMT2蛋白中可能的结合模式和关键的活性位点相互作用。对接结果是对实验结果的补充。
查看更多